We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neutralizing antibody responses to SARS-CoV-2 and Its Clinical implications.
- Authors
Yoonjung Kim; Sohyun Bae; Soyoon Hwang; Kitae Kwon; Hyun-Ha Chang; Shin-Woo Kim; Joon-Yong Bae; Manseong Park
- Abstract
배경 The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. However, until now, no specific treatment or vaccine has been identified for COVID-19 infections, and it is not yet known how long the antibodies, including defensive neutralizing antibody (Nab), will last in patients with COVID-19. In order to treat for the COVID-19 infection and to have data for the development of SARS-CoV-2 vaccines, research of antibody characteristics according to clinical manifestation is urgently needed. 방법 From Jun 3rd to Jun 23th, blood samples were collected from 143 PCR-confirmed COVID-19 recovered patients who agreed to participate in the antibody tracking study at the Kyungpook National University Hospital. Patients under 18 years or with mental illness were excluded. Nab analysis (plaque reduction neutralization test; PRNT) was conducted by Korea University. A survey of clinical features was conducted through an individualized questionnaire, and an epidemiological and clinical data from Daegu City. We evaluated the relations of the clinical characteristics and Nab titer (≥1:40 or <1:40). 결과 Of the total 143 patients, 68 (47.6 %) were male and 75 (52.4 %) were female. Age distribution was as follows: 34 (23.8%) patients age range 20-29; 24 (16.8%) patients age range 30-39; 25 (17.5%) patients age range 40-49; 27 (18.9%) patients age range 50-59; and 33 (23.1%) patients age range 60-69. The average days taken from the symptom onset to the blood collection date was 109.0 [104.0; 115.0]. 32 patients (22.4%) showed < 1:40 Nab titer and 111 patients (77.6%) showed ≥1:40. As time went by, the rate of Nab titer ≥1:40 showed a tendency to slow decrease (figure 1). As the age was older, the rate of Nab titer ≥1:40 showed a statistically significance increasing tendency (p<0.001)(figure 2). The symptoms of dyspnea and presence of pneumonia were statistically significantly higher in groups of ≥1:40, but there were no other symptoms differences, including fever, sore throat, ageusia, anosmia and upper respiratory symptoms. No statistical differences were identified in gender, underlying diseases and ICU admission history between the two groups. 결론 After 3 months of COVID-19 infection, all recovered patients were found to have Nab, and 77.6% showed Nab levels ≥1:40. In order to prepare the convalescent serum antibody treatment and to establish vaccine policies in the near future, continuous tracking of changes in Nab is needed.
- Subjects
KORYO Taehakkyo; SARS-CoV-2; ANTIBODY formation; COVID-19 pandemic; VACCINE development; COVID-19
- Publication
Infection & Chemotherapy, 2020, Vol 52, pS319
- ISSN
2093-2340
- Publication type
Article